ArticleOncotarget2017

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.

Lauren MacDonagh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.